Vanda Pharmaceuticals Inc.
VNDA
$3.92
-$0.06-1.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -5.91% | 11.61% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.91% | 11.61% | |||
| Cost of Revenue | 35.95% | 1.53% | |||
| Gross Profit | -8.05% | 12.18% | |||
| SG&A Expenses | 27.50% | 4.55% | |||
| Depreciation & Amortization | 0.00% | 0.06% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 43.50% | 8.21% | |||
| Operating Income | -299.14% | 6.55% | |||
| Income Before Tax | -475.16% | -4.05% | |||
| Income Tax Expenses | -396.78% | -72.28% | |||
| Earnings from Continuing Operations | -500.45% | 7.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -500.45% | 7.74% | |||
| EBIT | -299.14% | 6.55% | |||
| EBITDA | -370.08% | 8.05% | |||
| EPS Basic | -498.46% | 7.88% | |||
| Normalized Basic EPS | -175.93% | -115.82% | |||
| EPS Diluted | -459.89% | 1.53% | |||
| Normalized Diluted EPS | -175.93% | -115.82% | |||
| Average Basic Shares Outstanding | 0.38% | 0.08% | |||
| Average Diluted Shares Outstanding | 0.38% | 0.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||